-
1
Bispecific antibodies (BsAbs) engage T cells to target multiple myeloma (MM) cells, showing promising responses in heavily pre-treated patients.
-
2
Current BsAbs target antigens like BCMA and GPRC5D, which are highly expressed on malignant plasma cells, offering potential therapeutic benefits.
-
3
BCMA is a key target in MM therapy, with its expression linked to disease progression and poor outcomes, making it a valuable biomarker.
-
4
GPRC5D is a novel target that remains unaffected by BCMA loss, allowing for continued treatment options after BCMA therapies fail.
-
5
The manageable side effects of BsAbs, including low-grade cytokine release syndrome, enhance their appeal as an addition to existing MM treatments.
